Multiple Myeloma in Relapse Not Yet Recruiting Phase 1 Trials for Ibrutinib (DB09053)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs